Primary Packaging Pressure Pickle

All Situation Room examples are constructed and not descriptions of actual events.

Published on: October 5, 2024
Walter Routh
Categories: The Situation Room
Share This Article with the Stability Community!

What is the stability situation?

We’re approaching clinical trials for our solid dose antihistamine type medication packaged in blisters. All developmental stability studies were performed in an Aclar blister with foil backing from suppliers we are familiar with for our other product lines. Now procurement is pushing to change suppliers (more local and diverse), insisting that the alternative is identical with the same type of Aclar resin. To expedite time to market, the plan being pushed is to initiate clinicals and primary stability simultaneously, mind you, without any new extractable or leachable studies. A justification, primarily arguing for equivalency will be included in the filing.

As the director of quality, including the stability program, it seems up to me to put the brakes on what could be a very harmful decision—at the very least harmful to commercialization but possibly even to the clinical participants. In my presentation to the development gating committee (the group approving initiation of clinical trials) I want to give a fair and balanced stability risk assessment.

What are some key points I should focus on to get the most impact from my presentation?

How should this be resolved?

At the very least there must have been some sort of supplier qualifications performed for these local vendors. It’s hard to believe they would not have used this proposed new packaging and compared it to the previous data with some stability study. If not, then you are looking at a 483 simply for not properly qualifying this supplier. That alone should put the brakes on.

We Want to Hear Your Thoughts!

  • February 7, 2025

    Upper management has a dangerously low awareness and vigilance of stability. They haven’t had a significant event or audit observation to raise alarms and put us at top of mind. As a result, we get the dregs of personnel and budget—this needs to change.

  • January 4, 2025

    Samples swapped identities when human error caused incorrect storage conditions to be tested, but the only evidence is historical data trends. How can they prevent the error and shore up sample integrity?

  • December 7, 2024

    When an unidentified impurity pops up on stability testing of a topical drug-containing cosmetic, internal political conflict erupts regarding filing strategies. Should they delay filing and ID the impurity or push ahead favoring the cosmetic side of the product?

Share your questions and experiences

A stabilitarian encounters new situations every day. StabilityHub’s discussion forums give Stabilitarians an opportunity to ask questions and offer solutions to specific scenarios. Join in the conversations with other Stabilitiarians and share your knowledge!

A stabilitarian encounters new situations every day. StabilityHub’s discussion forums give Stabilitarians an opportunity to ask questions and offer solutions to specific scenarios. Join in the conversations with other Stabilitiarians and share your knowledge!